3B BlackBio Dx Ltd — Important, 03-06-2026: Company Update

The company released the transcript of its analyst/investor call for the financial results of the quarter and financial year. Consolidated revenue for the financial year reached INR142 Cr with a PAT of INR60 Cr. The molecular diagnostic business in India grew by approximately 10% to INR86.47 Cr, with international operations also showing strong growth. The company is actively pursuing US regulatory approvals for its acquired Belgian unit's products and adapting to European regulatory changes, targeting 15-20% revenue and EBITDA growth for the coming financial year. Management is also actively seeking M&A opportunities, holding significant cash reserves for strategic acquisitions.